Sounds like Habets' anecdata is worth less than nothing in that case.
Can anyone link me to JE's comment about this?
All patients were at least moderate though. The two (i think) severe patients didnt respond but nor did 3 moderate, and what they had in common was low NK cells. I don't think...
Is he using the same dosing schedule as the trials? Has he at least checked NK numbers before dosing patients?
I don't approve of his methods but if what he's saying is true that is a bit worrying.
Isn't he using sub clinical doses of teclistamab when he prescribes that anyway?
Agreed on the trademark front.
It seems like they released data from ten participants earlier this year.
They're claiming differences in t cells but also marked differences IFN-G, IL2, IL-10 and granzyme B
Wasnt there another flurospot or elispot study that showed elevated ifn-g in long...
Surely if we want to find out whether certain kinds of t cells and cytokines are involved in Me/CFS a test like this would be a useful tool to help figure that out?
So when will we likely see the results of this study?
Primary completion is all patients dosed and followed up and everything right? And study completion means like paper written and sent out for publication etc? Or does primary mean paper drafted too?
I seem to recall a lot of studies have an...
If what Younger presents in this video holds up then this is absolutely huge. But I guess we have to wait for the paper to make any real judgement. He says he's working on a brain lactate one first so might be a while.
I've been quite skeptical about some of his recent statements, but I'm...
I've mentioned this quite a few times on here but one of the first things to go wrong with my health was developing some sort of non 24 hour sleep disorder when I was 19. I strongly suspect now this was a prodromal phase of ME/CFS.
I had somehow missed that there wasn't a control group in this study.
We see so many studies without controls. Is recruiting them really so hard/expensive?
This gives some creedence to the idea discussed in the thread for the 2019 paper that GDF15 might only be higher in mild and moderate pwME during PEM/post exertion.
I also feel like this study could be on to something, and think it could gel with a lot of what we've been talking about this year. I would like to see a bigger study, especially one in ME/CFS.
I'd very much be interested to hear what @Jonathan Edwards thinks about it. Both about the study...
In your view is there any form of legal challenge that could potentially be successfully in forcing the government to deliver appropriate services (physician led with specialist nurses and home visits rather than 'multidisciplinary' clinics staffed by OTs and physios) for pwME?
Ok so if they have successfully got the government to deliver services for severe and vs pwME, and as we fear they have asked for the wrong things, does this preclude a similar legal campaign from asking for the right things? Or make the chances of success more likely by setting a precident?
Having come across this study, I find it surprising (but perhaps not that surprising given the state of the field) that there has been no replication attempt.
How do we feel about this study six years on? Do we still think it has potential as a biomarker/drug target?
I think the idea that...
Are there drugs on the market that target this pathway?
Is this model positing that the abberant signalling is occuring exclusively in nasal tissues or elsewhere too?
And do we think this type of issue could cause the symptoms of ME/CFS?
I was thinking along these lines earlier before you posted this! Great minds!
The daratumumab example is good because it could be many different things - 2 different diseases, sub optimal drug effectiveness linked to NK cell levels, nk cell levels as a marker for something else etc.
My main...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.